Strategies to overcome the side effects of chimeric antigen receptor T cell therapy-Reference-Cited by-同舟云学术

Strategies to overcome the side effects of chimeric antigen receptor T cell therapy

Published:2022-01-04 Issue:1 Volume:1510 Page:18-35
ISSN:0077-8923
Container-title:Annals of the New York Academy of Sciences
language:en
Short-container-title:Annals NY Academy of Science

Author:

Mirzaee Godarzee Mohadeseh¹,Mahmud Hussen Bashdar²,Razmara Ehsan³^ORCID,Hakak‐Zargar Benyamin⁴^ORCID,Mohajerani Fatemeh¹,Dabiri Hamed¹,Fatih Rasul Mohammed⁵,Ghazimoradi Mohammad Hossein¹,Babashah Sadegh¹^ORCID,Sadeghizadeh Majid¹

Affiliation:

1. Department of Molecular Genetics, Faculty of Biological Sciences Tarbiat Modares University Tehran Iran

2. Department of Pharmacognosy, College of Pharmacy Hawler Medical University Erbil Iraq

3. Australian Regenerative Medicine Institute Monash University, Clayton, Victoria, Australia, 3800

4. Faculty of Health Sciences Simon Fraser University Burnaby British Columbia Canada

5. Department of Medical Analysis, Faculty of Sciences Tishk International University Erbil Iraq

Publisher

Wiley

Subject

History and Philosophy of Science,General Biochemistry, Genetics and Molecular Biology,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/nyas.14724

Reference188 articles.

1. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain.

2. In vivo antitumor activity of T cells redirected with chimeric antibody/T cell receptor genes;Hwu P.;Cancer Res,1995

3. CAR T cells for infection, autoimmunity and allotransplantation

4. Recent advances in CAR-T cell engineering

5. Novartis.2017.Novartis receives first ever FDA approval for a CAR‐T cell therapy Kymriah(TM) (CTL019) for children and young adults with B cell ALL that is refractory or has relapsed at least twice.https://www.novartis.com/news/media-releases/novartis-receives-first-ever-fda-approval-car-t-cell-therapy-kymriahtm-ctl019-children-and-young-adults-b-cell-all-refractory-or-has-relapsed-least-twice

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control;Science Advances;2024-02-23

2. TSHR-based chimeric antigen receptor T cell specifically deplete auto-reactive B lymphocytes for treatment of autoimmune thyroid disease;International Immunopharmacology;2023-11

3. Respiratory syncytial virus–approved mAb Palivizumab as ligand for anti-idiotype nanobody-based synthetic cytokine receptors;Journal of Biological Chemistry;2023-11